Ask a Patient® Health News: Drugs & Treatments

Ask a Patient® Health News: Drugs & Treatments

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
Drug Safety Updates March 2024: Part 2
Copy link
Facebook
Email
Notes
More
User's avatar
Discover more from Ask a Patient® Health News: Drugs & Treatments
Official newsletter of Ask a Patient® website. Find out about new drugs, safety alerts, promising research, medication and supplements tips. Sent every other week.
Over 3,000 subscribers
Already have an account? Sign in
Drug Safety Updates

Drug Safety Updates March 2024: Part 2

Katie Rowley
Mar 17, 2024
4

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
Drug Safety Updates March 2024: Part 2
Copy link
Facebook
Email
Notes
More
Share

Drug Quality Testing Project

Have you ever switched from a brand name drug to a generic, or switched between generics, and found that the new drug didn't work as well or brought on new side effects?

Sometimes, drug quality is the reason for bad side effects, and only laboratory testing can pinpoint the specific quality problem. But the FDA does not require routine testing of drugs entering the U.S. Inadequate inspections of overseas manufacturing facilities have also contributed to drug safety problems. In fact, Bloomberg News reports that recalls related to drug manufacturing quality doubled in the US from 2018 to 2022.

Recently, independent drug testing company Valisure (New Haven, Connecticut) was awarded a contract with the U.S. Defense Department (DoD) to do medication quality testing. Along with multiple study partners, they are launching the Pharmaceutical Quality Risk Assessment Study to independently study the quality of generic drugs in the United States and create a “Red/Yellow/Green” rating system to help industry purchasers and patients avoid products with concerning results.

If you or someone you know has had an issue with a generic drug, please consider submitting it as a suggested drug to be included in the Pharmaceutical Quality Risk Assessment Study. You may submit more than one suggestion, but please fill out a separate form for each drug, along with the reasons you are recommending that the drug be tested. Find the link to the short survey here (click the blue “Vote” button on the page):
https://www.valisure.com/valisure-newsroom/vote-participate-in-the-largest-independent-pharmaceutical-quality-study

Infographic on lack of testing leads to 100 recalls per year - Valisure
Lack of Testing Leads to Drug Safety Problems. Image Source: Valisure Inc.

For an explanation of ingredient concentration variations, check out the Ask a Patient explainer on generics ingredients "Generic Drugs: Ingredients and Quality Concerns.”


Drug Safety Labeling Updates

Jazz Pharma's epilepsy drug Epidiolex (cannabidiol, a cannabinoid drug) had a safety label update to report post marketing cases of liver injury and liver enzyme elevations. Cases of elevated ammonia levels occurred in some patients who reported concomitant use of seizure drugs valproate, clobazam, or both.
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2298


Novo Nordisk's weight loss drug Wegovy (semaglutide) had its safety label updated with clinical trials data for geriatric patients. In the cardiovascular outcomes trial, patients age 75 years and older reported more fractures of the hip and pelvis on WEGOVY than on placebo.
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2711

Wegovy patient reviews on AskaPatient website


Genentech's flu drug Xofluza (baloxavir marboxil in liquid and tablet form) had its safety label updated to include pediatric (age 5 – 11) clinical trials results for patients at high risk of developing flu complications. The FDA approved the expanded use of the drug for these high risk patients. The most frequently reported adverse events for XOFLUZA treatment arm were vomiting (5%) and diarrhea (5%). Vomiting was reported in more patients who took oseltamivir (Tamiflu brand name), with 18% of subjects experiencing the side effect. The label notes that there are limited safety data in patients 5 to <12 years at high risk of developing influenza complications, as only 15 patients in this category were included in the study.
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2087

Xofluza and Tamiflu patient reviews on AskaPatient website


Motion sickness drug skin patch Transderm Scop (scopolamine) had a safety label update to warn of the risk of psychiatric adverse reactions. Patients with this experience are advised to remove the patch at once and seek medical attention if severe symptoms persist.  Also, because of the risk of blurred vision if the product comes in contact with the eyes, patients are advised to not touch the system while wearing it, and wash hands and the application site with soap and water after transdermal system removal.
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1887

Transderm Scop patch reviews at AskaPatient website


Benzene in Acne Products

Independent lab Valisure tested various acne products containing benzoyl peroxide, and found the carcinogen benzene in the products when they were subjected to "stability testing." Unlike Valisure's previous findings of benzene in sunscreens, hand sanitizers and other consumer products where the benzene came from contaminated raw materials, the benzene in benzoyl peroxide products come from the drug itself degrading into benzene. Valisure is asking the FDA to consider a market withdrawal.
https://fortune.com/well/2024/03/06/popular-acne-products-from-proactiv-clinique-and-target-contain-cancer-linked-chemical-benzene/


Readers, please note: the regular edition of Drugs & Treatments News will be sent tomorrow, March 18.


Subscribe to Ask a Patient® Health News: Drugs & Treatments

By Katie Rowley · Launched 2 years ago
Official newsletter of Ask a Patient® website. Find out about new drugs, safety alerts, promising research, medication and supplements tips. Sent every other week.
4

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
Drug Safety Updates March 2024: Part 2
Copy link
Facebook
Email
Notes
More
Share

Discussion about this post

User's avatar
May 2025 Safety Update: Duloxetine Recall; New Warnings for Gabapentin, Lyrica, Doxycycline, Other Antibiotics; Animal Testing Changes; FDA…
Duloxetine Recall
May 4 • 
Katie Rowley
2

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
May 2025 Safety Update: Duloxetine Recall; New Warnings for Gabapentin, Lyrica, Doxycycline, Other Antibiotics; Animal Testing Changes; FDA Delays Continue; Medication Tips
Copy link
Facebook
Email
Notes
More
July 23, 2023: Rx-OTC mini-pill approved; new leukemia drug; RSV preventive med for babies; psychedelics as meds; stakeholders weigh in…
New Drug Approvals
Jul 23, 2023
8

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
July 23, 2023: Rx-OTC mini-pill approved; new leukemia drug; RSV preventive med for babies; psychedelics as meds; stakeholders weigh in; safety of new heart drug; thyroid drug side effects
Copy link
Facebook
Email
Notes
More
February 18, 2024: New drugs for food allergy, melanoma, frostbite, acetaminophen overdose; new pharma ads rules; reducing cancer drug side…
New Drug Approvals
Feb 19, 2024
1

Share this post

Ask a Patient® Health News: Drugs & Treatments
Ask a Patient® Health News: Drugs & Treatments
February 18, 2024: New drugs for food allergy, melanoma, frostbite, acetaminophen overdose; new pharma ads rules; reducing cancer drug side effects; preventing "senior moments;"and more
Copy link
Facebook
Email
Notes
More

Ready for more?

© 2025 AskaPatient.com
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More

Create your profile

User's avatar

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.